---
title: "Afternoon of the third day of the 2025 National Conference: Representatives from companies such as Novartis, Roche, and Betta Pharmaceuticals enter"
description: "According to a reporter from the Financial Associated Press, at the on-site negotiations for the 2025 National Medical Insurance Catalog and the price negotiations for innovative drugs under commercia"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263832503.md"
published_at: "2025-11-01T06:29:10.000Z"
---

# Afternoon of the third day of the 2025 National Conference: Representatives from companies such as Novartis, Roche, and Betta Pharmaceuticals enter

> According to a reporter from the Financial Associated Press, at the on-site negotiations for the 2025 National Medical Insurance Catalog and the price negotiations for innovative drugs under commercial insurance, the afternoon session of the 2025 national negotiations began around 1:40 PM, with companies including Novartis, Gensight, Roche, and Betta Pharmaceuticals participating. Observations from the site indicated that the focus of today's morning negotiations was on chronic disease medications, including diabetes drugs, with Eli Lilly and Yino Pharma bringing significant products to the negotiations

According to a reporter from the Financial Associated Press, at the on-site negotiations for the 2025 National Medical Insurance Catalog and the price negotiations for the innovative drug catalog of commercial insurance, the afternoon session of the 2025 national negotiations began around 1:40 PM. Companies present included Novartis, Gensai, Roche, and Betta Pharmaceuticals. Observations from the site indicated that the focus of today's morning negotiations was on chronic disease medications, including diabetes drugs, with Eli Lilly and Yino Pharmaceutical bringing significant products to the negotiations

### Related Stocks

- [RHHBY.US - Roche](https://longbridge.com/en/quote/RHHBY.US.md)
- [0BDYY.HK - 贝达药业](https://longbridge.com/en/quote/0BDYY.HK.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 惠誉在更新公司评级标准后维持了对 Hikma 和罗氏的评级 | 惠誉在更新企业评级标准后维持对 Hikma 和罗氏 (ADR) 的评级 | [Link](https://longbridge.com/en/news/275874477.md) |
| 罗氏报告 2025 财年归属净收入和销售额增长 | 罗氏报告 FY25 可归属净收入和销售额增长 | [Link](https://longbridge.com/en/news/274100655.md) |
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |
| 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元 | 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| 在诺华制药（SWX:NOVN）经历多年强劲的股价上涨后，现在是否为时已晚再考虑投资？ | 诺华制药的股票目前价格为 121.00 瑞士法郎，显示出强劲的动能，并在多个时期内获得了显著回报。估值检查表明该股票被低估，DCF 分析显示每股内在价值为 250.98 美元，表明有 51.8% 的折扣。21.53 倍的市盈率低于行业平均水 | [Link](https://longbridge.com/en/news/275655673.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.